Immunic (NASDAQ:IMUX) Posts Earnings Results, Beats Estimates By $0.05 EPS

Immunic (NASDAQ:IMUX) posted its quarterly earnings results on Thursday. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.05, Zacks reports.

Immunic Trading Down 5.5%

Shares of IMUX traded down $0.04 during trading hours on Thursday, hitting $0.72. The company had a trading volume of 910,824 shares, compared to its average volume of 1,287,352. The company has a market capitalization of $70.83 million, a PE ratio of -0.77 and a beta of 1.53. Immunic has a one year low of $0.56 and a one year high of $1.42. The company’s fifty day moving average price is $0.83 and its two-hundred day moving average price is $0.87.

Analysts Set New Price Targets

A number of brokerages have commented on IMUX. Roth Capital assumed coverage on shares of Immunic in a research note on Friday, November 7th. They issued a “buy” rating and a $3.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunic in a report on Wednesday, October 8th. D. Boral Capital reduced their price objective on Immunic from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Immunic in a report on Friday, September 26th. Finally, Chardan Capital started coverage on Immunic in a research note on Monday, September 29th. They set a “buy” rating and a $13.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Immunic presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.80.

Hedge Funds Weigh In On Immunic

An institutional investor recently raised its position in Immunic stock. Jane Street Group LLC lifted its stake in Immunic, Inc. (NASDAQ:IMUX) by 279.3% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 207,401 shares of the company’s stock after buying an additional 152,726 shares during the quarter. Jane Street Group LLC owned approximately 0.22% of Immunic worth $226,000 as of its most recent SEC filing. Institutional investors and hedge funds own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.